197 related articles for article (PubMed ID: 30076411)
1. Mouse ER+/PIK3CA
Stratikopoulos EE; Kiess N; Szabolcs M; Pegno S; Kakit C; Wu X; Poulikakos PI; Cheung P; Schmidt H; Parsons R
Oncogene; 2019 Jan; 38(1):47-59. PubMed ID: 30076411
[TBL] [Abstract][Full Text] [Related]
2. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
[TBL] [Abstract][Full Text] [Related]
3. ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins.
Alcon C; Gómez Tejeda Zañudo J; Albert R; Wagle N; Scaltriti M; Letai A; Samitier J; Montero J
Cells; 2021 Jul; 10(7):. PubMed ID: 34359829
[TBL] [Abstract][Full Text] [Related]
4. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.
Merino D; Lok SW; Visvader JE; Lindeman GJ
Oncogene; 2016 Apr; 35(15):1877-87. PubMed ID: 26257067
[TBL] [Abstract][Full Text] [Related]
5. Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.
Yang W; Hosford SR; Dillon LM; Shee K; Liu SC; Bean JR; Salphati L; Pang J; Zhang X; Nannini MA; Demidenko E; Bates D; Lewis LD; Marotti JD; Eastman AR; Miller TW
Clin Cancer Res; 2016 May; 22(9):2250-60. PubMed ID: 26733612
[TBL] [Abstract][Full Text] [Related]
6. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
[TBL] [Abstract][Full Text] [Related]
7. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.
Faber AC; Farago AF; Costa C; Dastur A; Gomez-Caraballo M; Robbins R; Wagner BL; Rideout WM; Jakubik CT; Ham J; Edelman EJ; Ebi H; Yeo AT; Hata AN; Song Y; Patel NU; March RJ; Tam AT; Milano RJ; Boisvert JL; Hicks MA; Elmiligy S; Malstrom SE; Rivera MN; Harada H; Windle BE; Ramaswamy S; Benes CH; Jacks T; Engelman JA
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1288-96. PubMed ID: 25737542
[TBL] [Abstract][Full Text] [Related]
8. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
[TBL] [Abstract][Full Text] [Related]
9. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.
Bosch A; Li Z; Bergamaschi A; Ellis H; Toska E; Prat A; Tao JJ; Spratt DE; Viola-Villegas NT; Castel P; Minuesa G; Morse N; Rodón J; Ibrahim Y; Cortes J; Perez-Garcia J; Galvan P; Grueso J; Guzman M; Katzenellenbogen JA; Kharas M; Lewis JS; Dickler M; Serra V; Rosen N; Chandarlapaty S; Scaltriti M; Baselga J
Sci Transl Med; 2015 Apr; 7(283):283ra51. PubMed ID: 25877889
[TBL] [Abstract][Full Text] [Related]
10. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
[TBL] [Abstract][Full Text] [Related]
11. Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER
Hosford SR; Dillon LM; Bouley SJ; Rosati R; Yang W; Chen VS; Demidenko E; Morra RP; Miller TW
Clin Cancer Res; 2017 Jun; 23(11):2795-2805. PubMed ID: 27903677
[No Abstract] [Full Text] [Related]
12. Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
Merino VF; Cho S; Liang X; Park S; Jin K; Chen Q; Pan D; Zahnow CA; Rein AR; Sukumar S
Mol Oncol; 2017 May; 11(5):552-566. PubMed ID: 28296140
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen.
Chen IC; Hsiao LP; Huang IW; Yu HC; Yeh LC; Lin CH; Wei-Wu Chen T; Cheng AL; Lu YS
Sci Rep; 2017 Aug; 7(1):9842. PubMed ID: 28852212
[TBL] [Abstract][Full Text] [Related]
14. Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.
Bhola NE; Jansen VM; Bafna S; Giltnane JM; Balko JM; Estrada MV; Meszoely I; Mayer I; Abramson V; Ye F; Sanders M; Dugger TC; Allen EV; Arteaga CL
Cancer Res; 2015 Jan; 75(2):405-14. PubMed ID: 25480943
[TBL] [Abstract][Full Text] [Related]
15. Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers.
Hata AN; Yeo A; Faber AC; Lifshits E; Chen Z; Cheng KA; Walton Z; Sarosiek KA; Letai A; Heist RS; Mino-Kenudson M; Wong KK; Engelman JA
Cancer Res; 2014 Jun; 74(11):3146-56. PubMed ID: 24675361
[TBL] [Abstract][Full Text] [Related]
16. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.
Faber AC; Corcoran RB; Ebi H; Sequist LV; Waltman BA; Chung E; Incio J; Digumarthy SR; Pollack SF; Song Y; Muzikansky A; Lifshits E; Roberge S; Coffman EJ; Benes CH; Gómez HL; Baselga J; Arteaga CL; Rivera MN; Dias-Santagata D; Jain RK; Engelman JA
Cancer Discov; 2011 Sep; 1(4):352-65. PubMed ID: 22145099
[TBL] [Abstract][Full Text] [Related]
17. Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations.
Yuan W; Stawiski E; Janakiraman V; Chan E; Durinck S; Edgar KA; Kljavin NM; Rivers CS; Gnad F; Roose-Girma M; Haverty PM; Fedorowicz G; Heldens S; Soriano RH; Zhang Z; Wallin JJ; Johnson L; Merchant M; Modrusan Z; Stern HM; Seshagiri S
Oncogene; 2013 Jan; 32(3):318-26. PubMed ID: 22370636
[TBL] [Abstract][Full Text] [Related]
18. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.
Loi S; Haibe-Kains B; Majjaj S; Lallemand F; Durbecq V; Larsimont D; Gonzalez-Angulo AM; Pusztai L; Symmans WF; Bardelli A; Ellis P; Tutt AN; Gillett CE; Hennessy BT; Mills GB; Phillips WA; Piccart MJ; Speed TP; McArthur GA; Sotiriou C
Proc Natl Acad Sci U S A; 2010 Jun; 107(22):10208-13. PubMed ID: 20479250
[TBL] [Abstract][Full Text] [Related]
19. B cell lymphoma-2 (BCL-2) homology domain 3 (BH3) mimetics demonstrate differential activities dependent upon the functional repertoire of pro- and anti-apoptotic BCL-2 family proteins.
Renault TT; Elkholi R; Bharti A; Chipuk JE
J Biol Chem; 2014 Sep; 289(38):26481-26491. PubMed ID: 25096574
[TBL] [Abstract][Full Text] [Related]
20. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]